Sources

10 Total Sources

Compass Pathways Posts 26-Week Phase 3 COMP360 Data, Eyes H1 2027 TRD Launch

Center100%

Psychedelic Alpha13h ago

Compass Pathways Releases 26-Week COMP360 Psilocybin Phase 3 Data for TRD

Yahoo! Voices13h ago

Compass' psilocybin shows six-month durability in Phase III trial

BioSpace11h ago

Compass' psilocybin depression drug works for the long haul - BioSpace

thefrontierpsychiatrists.substack.com12h ago

Lil John and Owen Muir Respond to Compass Pathways Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile for Comp360

Minichart13h ago

Compass Pathways' COMP360 Psilocybin Shows Rapid, Durable Efficacy and Safety in Phase 3 Trials for Treatment-Resistant Depression – FDA Approval Expected 2027 2456 – Minichart

Investing.com13h ago

Compass Pathways reports 6-month data from phase 3 TRD trial By Investing.com

StockTitan13h ago

Compass Pathways posts positive Phase 3 TRD data | CMPS 8-K Filing

ir.compasspathways.com13h ago

Compass Pathways - Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Psychiatric Times13h ago

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD | Psychiatric Times

MD Magazine13h ago

COMP360 Psilocybin Sustains Depression Benefit Through 26 Weeks | HCPLive